AVT001
Type 1 Diabetes
About Avotres
Avotres is a clinical-stage biotech pioneering a novel approach to restore immune self-tolerance. Its lead asset, AVT001, is a cell therapy targeting the Q/E CD8+ Treg pathway, with a completed Phase I/II trial in Type 1 Diabetes and plans for a Phase III trial, as well as a Phase IIb study in Multiple Sclerosis. The company's platform has the potential to address a broad spectrum of autoimmune conditions and transplant rejection, and it is also developing an early-stage monoclonal antibody, AVT002, for oncology. Backed by venture capital, Avotres is advancing a multi-asset pipeline toward high-value clinical milestones.
View full company profileAbout Avotres
Avotres is a clinical-stage biotech pioneering a novel approach to restore immune self-tolerance. Its lead asset, AVT001, is a cell therapy targeting the Q/E CD8+ Treg pathway, with a completed Phase I/II trial in Type 1 Diabetes and plans for a Phase III trial, as well as a Phase IIb study in Multiple Sclerosis. The company's platform has the potential to address a broad spectrum of autoimmune conditions and transplant rejection, and it is also developing an early-stage monoclonal antibody, AVT002, for oncology. Backed by venture capital, Avotres is advancing a multi-asset pipeline toward high-value clinical milestones.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |